Companies /Healthcare

Thermo Fisher Scientific Inc

NYSE: TMO Diagnostics & Research
$684.03
▼ $22.13 (−3.13%) today
Markets open · 3:07pm ET

24/7 Wall St. View

Price Prediction $801.40 +13.5% Our analysts’ 12-month view: target, optimistic case, and floor. TMO price prediction →

TMO at a Glance

Valuation
Market cap
$261.6B
P/E ratio
37.2
Dividend yield
0.26%
Profitability
Revenue (TTM)
$47.4B
Profit margin
14.9%
EPS (TTM)
$18.96
Price
52-week range
$435 – $712
24/7 target
$801.40
Street target
$752.12
Earnings
Next report
Jan 27, 2027

Headquartered in Waltham, MA Fiscal year ends December NYSE: TMO thermofisher.com

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) serves science globally with annual revenue exceeding $45 billion. The company enables customers to make the world healthier, cleaner and safer by supporting life sciences research, solving complex analytical challenges, increasing laboratory productivity, improving patient health through diagnostics, and aiding in the development and manufacture of life-changing therapies. Thermo Fisher delivers an extensive combination of innovative technologies, purchasing convenience and pharmaceutical services through its portfolio of brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Gibco, Fisher Scientific, Unity Lab Services, Patheon and PPD. The company operates through four reportable segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. Its product and service offerings span mass spectrometry, electron microscopy, genomic sequencing, proteomics, autoimmune diagnostics, laboratory distribution channels, pharmaceutical contract development and manufacturing, and clinical research services. Updated

Latest Activity

Jim Cramer
PodcastMad Money w/ Jim CramerJim Cramer · 44 min

Mad Money w/ Jim Cramer 11/3/26

  • Cramer calls the mega caps millstones: Nasdaq rose 0.83% while the Dow fell 197 points
  • Strong after-hours results from AMD and Arista Networks as proof non-Magnificent-Seven tech can lead
  • Oracle's $10 billion block priced at $116 and traded to $126, a sign buyers see a floor in tech
  • Wants a crescendo washout before committing more; Apple's reaction and a Palantir selloff weighed

The leadership baton is being passed to second-tier data center names, and Cramer would rather own companies with clean balance sheets than the big caps issuing debt and equity to stay in the AI race. He is not calling a bottom yet: without a high-volume reversal day, he keeps money elsewhere.

Read more
TMOThermo Fisher Scientific
New 52-week high$704.15+1.1% vs prior high · 2026-10-15

Thermo Fisher just printed a fresh 52-week high at $704.15, 1.1% above the peak it set on October 15. The $260.6 billion name has now clawed back everything it lost from April's $447 low.

Read more
Jim Cramer
PodcastMad Money w/ Jim CramerJim Cramer · 44 min

Mad Money w/ Jim Cramer 10/27/26

  • Cramer rejects the AI all-clear despite Broadcom arranging $63 billion in financing for Anthropic compute
  • Meta's $25 billion equity raise was five times oversubscribed, but the $60 billion at-the-market program worries him
  • CoreWeave bonds reaching a 15% yield flagged as the sector's unresolved weak spot
  • Caller questions on Micron volatility and Revolution Medicines' pancreatic cancer drug

The bull case for data centers today rested on financing rather than profits, and Cramer wants to hear a customer say the chips are minting money before calling it clear. He expects Meta's at-the-market selling to weigh on the stock as supply hits at the wrong moments, with borrowing costs into a Fed decision the swing factor for everything levered to the buildout.

Read more
Jim Cramer
PodcastMad Money w/ Jim CramerJim Cramer · 44 min

Mad Money w/ Jim Cramer 10/26/26

  • Cramer's bear case: a flood of IPOs and secondaries, $148B raised so far this year, drains the money that funds stocks
  • Applied Materials down from $739 to $387: buy 25 shares now, add on the pattern, finish in the 200s
  • Moderna after a parabolic move: let it come in before earnings, no buying parabolic charts
  • Thermo Fisher CEO on a beat-and-raise, BlackBerry's turnaround, and CrowdStrike cyber worries on deck

The call that matters for holders here is supply: Cramer argues the equity and debt markets are nearly tapped out after Meta, Alphabet and SpaceX raisings, with Anthropic's S1 now in line. He stops short of calling a top while pushing for buybacks and takeovers over further deals, favoring staged buying in Applied Materials and patience on Moderna.

Read more
TMOThermo Fisher Scientific
Regular session
$694.59
+4.27%open $666.14

An outsized 4.27% day for a life sciences giant, and it follows this morning's Q3 earnings beat. Keep an eye on whether the bid holds into the close.

Read more
TMOThermo Fisher Scientific
Regular session
$694.47
+4.25%open $666.14

A 4.25% jump to $694.47 follows this morning's Q3 earnings beat. The question now is whether life-science tools demand holds up past one quarter.

Read more
TMOThermo Fisher Scientific
Q3 2026
EPS
$6.68
est $6.40+4.3%
Revenue
$12.14B
est $11.95B+1.6%

Demand across life-sciences tools is holding up: Thermo Fisher beat on both lines with adjusted operating margin widening 120 basis points to 24.5%. Updated full-year guidance lands on this morning's call, so keep an eye on the stock.

Quarterly EPS — reported vs estimate
Read more
TMOThermo Fisher Scientific Inc.
Reports Wed Oct 21Before openConfirmed

Twelve straight quarters of EPS beats go on the line at 6:00 AM ET, with consensus at $6.40 on $11.95 billion in revenue. The real tell is whether life-science tools and bioprocessing demand held up well enough to extend the run.

    Read more
    TMOThermo Fisher Scientific
    New 52-week high$696.49+2.5% vs prior high · 2026-09-29

    Thermo Fisher just set a 52-week high at $696.49, roughly 56% above its March low. The $257.6 billion life-science tools name has never been priced higher in the past year.

    Read more
    TMOThermo Fisher Scientific
    After-hours
    $657.16
    -4.05%open $684.91

    A 4.05% slide to $657.16 is a heavy day for a $243 billion life sciences bellwether, erasing roughly $10 billion of market value. Keep an eye on whether the stock stabilizes near that level in the next session.

    Read more

    TMO Coverage

    Load More

    Frequently Asked Questions

    What does Thermo Fisher Scientific do?

    Thermo Fisher Scientific Inc. (NYSE: TMO) serves science globally with annual revenue exceeding $45 billion.

    What is the TMO stock price target?

    24/7 Wall St.'s 12-month price target for TMO is $801.40, rated Buy. The Wall Street consensus target is $752.12. TMO price prediction →